Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
340 participants
INTERVENTIONAL
2017-11-16
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05172258
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
NCT01345682
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT01064479
Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT03652233
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient Cohort B1
Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).
Afatinib
Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
standard of care
Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
Patient Cohort B2
Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
Afatinib
Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
standard of care
Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
Patient Cohort B3
Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
Palbociclib
Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
standard of care
Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
Patient Cohort B4
Patients who are p16 negative and 'platinum sensitive' SCCHN will receive niraparib
Niraparib
Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
Patient Cohort B5
Patients whith oropharyngeal cancer and which are p16 positive will receive niraparib
Niraparib
Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
Patient Cohort I1
Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).
IPH2201
protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Patient Cohort I2
Patient who are PD(L)1 pretreated will be randomized between monalizumab + durvalumab or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
standard of care
Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
IPH2201
protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Durvalumab
Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Patient Cohort I3
Patient who are progressing prior PD(L)1 after having received at least 2 months of anti-PD(L)-1 will receive INCAGN01876.
INCAGN01876
INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Afatinib
Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
Palbociclib
Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
standard of care
Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
IPH2201
protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Durvalumab
Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Niraparib
Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
INCAGN01876
INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least one measurable lesion by MRI or CT-scan according to RECIST 1.1, evaluated within 2 weeks prior to registration. Such lesion must not have been previously irradiated; if the measurable lesion(s) have been irradiated, clear progression must be documented.
* Progressive disease after first line platinum-based chemotherapy with or without cetuximab given as palliative treatment or progressive disease within 1 year if platinum-based chemotherapy was given as a part of the multimodal curative treatment. Patients pre-treated with anti-PD1/anti-PDL1 are allowed.
* ECOG performance status 0 -1 with a life expectancy of at least 12 weeks.
* Tumor core biopsy from any accessible tumor at the recurrent or metastatic site available for central testing.
* Patients must have adequate organ function, evaluated within 14 days prior to cohort allocation:
* Hemoglobin ≥ 9 g/100 ml,
* Neutrophils ≥ 1,500/mm3,
* Platelets ≥ 100,000/mm3,
* Total bilirubin \<1.5 times the upper limit of normal (ULN) (\< 3 times the upper limit of normal for Gilbert's disease),
* Serum ALT and AST ≤ 2.5 x ULN,
* Adequate renal function measured by:
* Estimated creatinine clearance ≥45ml using Cockcroft and Gault formula or Creatinine ≤ 1.5 ULN
* International Normalized Ratio (INR) or Prothrombin Time (PT) must be within the normal ranges as per institution's standard. A window of 5% is allowed.
* Patients receiving anticoagulant therapy are allowed to participate as long as the PT/INR values are within the expected target range of their current dose.
* Clinically normal cardiac function based on -left ventricular ejection fraction (≥ 50%) as assessed either by multi-gated acquisition scan or cardiac ultrasound and 12 lead ECG without clinically relevant abnormalities.
* Patients ≥ 18 years old and must be able to give written informed consent.
* Patients ≥ 70 years old must undergo the G8 screening.
* Women of child-bearing potential must have a negative pregnancy test (serum or urine within the 72 hours prior to cohort allocation).
* Patients of childbearing / reproductive potential must agree to use highly effective methods of contraception based on the Clinical Trial Facilitation Group (CTFG) guidance as of registration and up to 6 months after the last treatment dose. Highly effective methods can achieve failure rate of less than 1% per year when used consistently and correctly. Such methods include: For Women: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal and transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner and sexual abstinence. For Men: condoms, sexual abstinence (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient) and no sperm donations during treatment and up to 6 months after last dose of treatment.
* Female subjects who are breast feeding should agree to discontinue nursing prior to the first dose of study treatment and up to 6 months after the last study treatment.
* Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
Exclusion Criteria
* History of any of the following cardiovascular conditions within 6 months prior to registration:
* myocardial infarction,
* severe/unstable angina,
* ongoing cardiac dysrhythmias of CTCAE version 4.03 Grade 2 or more,
* atrial fibrillation of any grade,
* coronary/peripheral artery bypass graft,
* symptomatic congestive heart failure according to New York Heart Association (NYHA) Class III or Class IV,
* significant active cardiac disease including uncontrolled high blood pressure defined as systolic ≥150 and diastolic ≥100.
* cerebrovascular accident including transient ischemic attack
* thromboembolic events like symptomatic pulmonary embolism.
* Nasopharynx and sino-nasal tumor.
* Surgery or investigational drugs or chemotherapy or other anticancer therapy within 3 weeks before cohort allocationor or for investigational drugs, within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter. Participant must have recovered from any surgical procedure. Curative radiation therapy (60-70 Gy) within 6 weeks of cohort allocation. Palliative radiation therapy (e.g. 8 Gy on a painful lesion) will be allowed.
* Known untreated and uncontrolled brain metastases or leptomeningeal carcinomatosis.
* Known diagnosis of immune deficiency or a positive serology of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
* Active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected) or pre-existing liver cirrhosis.
* Known pre-existing interstitial lung disease (ILD). Bronchoemphysema is not considered as ILD.
* Other uncontrolled active illnesses or nonmalignant systemic disease (examples include, but are not limited to active infections requiring antibiotics, bleeding disorders, uncontrolled diabetes, uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome …).
* Any psychiatric, psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
* Any malignancy (other than SCCHN, non-melanoma skin cancer or localized cervical cancer or localized and presumed cured prostatic cancer or basal cell carcinoma of the skin and carcinoma in situ of the cervix or bladder) within the last 3 years prior to treatment allocation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Saint-Pierre-Site Porte de Hal
Brussels, , Belgium
Cliniques Universitaires Saint-Luc
Brussels, , Belgium
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, , Belgium
Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame
Charleroi, , Belgium
Universitair Ziekenhuis Antwerpen
Edegem, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
Hopital De Jolimont
Haine-Saint-Paul, , Belgium
AZ Groeninge Kortrijk - Campus Kennedylaan
Kortrijk, , Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, , Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, , Belgium
GasthuisZusters Antwerpen - Sint-Augustinus
Wilrijk, , Belgium
CHU Dinant Godinne - UCL Namur
Yvoir, , Belgium
CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre
Bordeaux, , France
Centre Georges-Francois-Leclerc
Dijon, , France
Centre Oscar Lambret
Lille, , France
Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau
Nantes, , France
Centre Antoine Lacassagne
Nice, , France
Institut Curie
Paris, , France
Institut de Cancerologie Strasbourg Europe
Strasbourg, , France
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, , France
Gustave Roussy
Villejuif, , France
Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, , Italy
IRCCS - Fondazione G. Pascale
Napoli, , Italy
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Napoli, , Italy
ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)
Barcelona, , Spain
Hospital Universitario 12 De Octubre
Madrid, , Spain
Hospital Clinico Universitario De Valencia
Valencia, , Spain
University Hospitals Birmingham NHS Foundation Trust (UHB) - UHB-Queen Elisabeth Medical Centre
Birmingham, , United Kingdom
NHS Lothian - Western General Hospital
Edinburgh, , United Kingdom
NHS Lothian - Western General Hospital
Edinburgh, , United Kingdom
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital
Glasgow, , United Kingdom
Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital
London, , United Kingdom
Oxford University Hospitals NHS Trust - Churchill Hospital
Oxford, , United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, Caballero C, Fortpied C, Bogaerts J, Govaerts AS, Staelens D, Raveloarivahy T, Rodegher L, Laes JF, Saada-Bouzid E, Machiels JP. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. Ann Oncol. 2018 Dec 1;29(12):2313-2327. doi: 10.1093/annonc/mdy452.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-000086-74
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
EORTC-1559-HNCG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.